WO2009104939A3 - 약제학적 제제 - Google Patents

약제학적 제제 Download PDF

Info

Publication number
WO2009104939A3
WO2009104939A3 PCT/KR2009/000856 KR2009000856W WO2009104939A3 WO 2009104939 A3 WO2009104939 A3 WO 2009104939A3 KR 2009000856 W KR2009000856 W KR 2009000856W WO 2009104939 A3 WO2009104939 A3 WO 2009104939A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical preparation
compartment
compartments
active component
hmg
Prior art date
Application number
PCT/KR2009/000856
Other languages
English (en)
French (fr)
Other versions
WO2009104939A2 (ko
Inventor
김성욱
전성수
조영관
구자성
손재운
김진욱
Original Assignee
한올제약주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한올제약주식회사 filed Critical 한올제약주식회사
Priority to CN2009801144445A priority Critical patent/CN102014881A/zh
Priority to US12/918,993 priority patent/US20110111021A1/en
Priority to EP09711817A priority patent/EP2255796A2/en
Publication of WO2009104939A2 publication Critical patent/WO2009104939A2/ko
Publication of WO2009104939A3 publication Critical patent/WO2009104939A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 약리학적 활성성분으로 레닌억제제를 포함하는 구획, 및 약리학적 활성성분으로 HMG-CoA환원효소억제제를 포함하는 구획을 포함하며, 상기 구획 중 하나의 구획은 선방출성 구획이고 나머지 하나의 구획은 지연방출성 구획인 약제학적 제제를 제공한다. 본 발명의 복합제제는 레닌억제제와 HMG-CoA환원효소억제제를 특정 속도로 시간차를 두고 송달 가능하므로, 부작용의 염려는 감소시키고 약효는 향상시키며, 복약지도는 용이하게 하는 장점을 갖는다. 또한, 상기 약물성분을 따로 또는 동시에 복용하는 복합 처방의 경우보다 대사 증후군, 심혈관 질환, 신장 질환 등의 예방 또는 치료에서 약리학적, 임상학적, 과학적 및 경제적으로 보다 유용한 효과를 달성할 수 있게 한다.
PCT/KR2009/000856 2008-02-22 2009-02-23 약제학적 제제 WO2009104939A2 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN2009801144445A CN102014881A (zh) 2008-02-22 2009-02-23 药物制剂
US12/918,993 US20110111021A1 (en) 2008-02-22 2009-02-23 Pharmaceutical preparation
EP09711817A EP2255796A2 (en) 2008-02-22 2009-02-23 Pharmaceutical preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0016518 2008-02-22
KR20080016518 2008-02-22

Publications (2)

Publication Number Publication Date
WO2009104939A2 WO2009104939A2 (ko) 2009-08-27
WO2009104939A3 true WO2009104939A3 (ko) 2009-11-19

Family

ID=40986074

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/000856 WO2009104939A2 (ko) 2008-02-22 2009-02-23 약제학적 제제

Country Status (5)

Country Link
US (1) US20110111021A1 (ko)
EP (1) EP2255796A2 (ko)
KR (1) KR101164300B1 (ko)
CN (1) CN102014881A (ko)
WO (1) WO2009104939A2 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2382969A1 (en) * 2010-04-30 2011-11-02 Sanovel Ilac Sanayi ve Ticaret A.S. Multicoated Aliskiren formulations
CN102247345A (zh) * 2011-05-30 2011-11-23 北京阜康仁生物制药科技有限公司 一种新型降血脂组合物
CN102283831B (zh) * 2011-09-03 2014-08-06 新乡医学院第一附属医院 一种治疗冠心病的西药复方及用途
KR20170012169A (ko) * 2015-07-24 2017-02-02 김병용 경구용 복합제제
KR102265977B1 (ko) * 2018-07-16 2021-06-16 주식회사 코피텍 방습성이 개선된 필름 코팅용 조성물 및 이를 코팅한 정제
CN113398273B (zh) * 2021-05-14 2022-07-19 广西壮族自治区中国科学院广西植物研究所 木聚糖衍生物作为亲水性缓释材料在制备药物缓释片中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010022508A (ko) * 1997-07-31 2001-03-15 추후보정 3-히드록시-3-메틸글루타릴 조효소 ａ 환원 효소 억제제와니코틴산 화합물의 조성물 및 야간에 1일 1회 투여하여고지질혈증을 치료하는 방법
KR20040079980A (ko) * 2002-02-01 2004-09-16 데포메드 인코퍼레이티드 속방성 및 서방성 약물 모두를 송달하는 경구 투약 형태의제조방법
KR20070078625A (ko) * 2006-01-27 2007-08-01 씨제이 주식회사 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
KR20080000624A (ko) * 2005-04-27 2008-01-02 노파르티스 아게 아테롬성동맥경화증의 치료 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
NZ520176A (en) * 1997-07-31 2005-02-25 Kos Life Sciences Inc Combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20080103105A1 (en) * 2006-09-22 2008-05-01 Braincells, Inc. HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010022508A (ko) * 1997-07-31 2001-03-15 추후보정 3-히드록시-3-메틸글루타릴 조효소 ａ 환원 효소 억제제와니코틴산 화합물의 조성물 및 야간에 1일 1회 투여하여고지질혈증을 치료하는 방법
KR20040079980A (ko) * 2002-02-01 2004-09-16 데포메드 인코퍼레이티드 속방성 및 서방성 약물 모두를 송달하는 경구 투약 형태의제조방법
KR20080000624A (ko) * 2005-04-27 2008-01-02 노파르티스 아게 아테롬성동맥경화증의 치료 방법
KR20070078625A (ko) * 2006-01-27 2007-08-01 씨제이 주식회사 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법

Also Published As

Publication number Publication date
WO2009104939A2 (ko) 2009-08-27
US20110111021A1 (en) 2011-05-12
EP2255796A2 (en) 2010-12-01
KR20090091081A (ko) 2009-08-26
CN102014881A (zh) 2011-04-13
KR101164300B1 (ko) 2012-07-09

Similar Documents

Publication Publication Date Title
WO2009104939A3 (ko) 약제학적 제제
MX2009004681A (es) Composicion compleja de liberacion controlada que comprende bloqueadores del receptor de angiotensina ii e inhibidores de hmg-coa-reductasa.
WO2011039768A3 (en) Pharmaceutical compositions for reducing alcohol-induced dose dumping
WO2010150995A3 (en) Compositions for treating drug addiction and improving addiction-related behavior
WO2008116195A3 (en) Compositions comprising an sglt2 ingibitor for treating obesity
WO2010056754A3 (en) Inhibition of mammalian target of rapamycin
BRPI0520082A2 (pt) formas de dosagem de risedronato
WO2009134086A3 (ko) 심혈관계 질환 치료용 약제학적 제제
WO2009125981A3 (ko) 약제학적 제제
WO2009088414A3 (en) Oral pharmaceutical dosage forms
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
WO2009022821A3 (en) Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same
EP2444072A3 (en) Non-mucoadhesive film dosage forms
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
WO2006083780A3 (en) Glucuronidated nebivolol
WO2008139271A3 (en) A synergistic pharmaceutical combination for the treatment of cancer
WO2009127922A3 (ko) 심혈관계 질환 치료용 약제학적 제제
WO2010033236A3 (en) Methods and compositions for treating bacterial infections by inhibiting quorum sensing
WO2010092450A8 (en) Stable pharmaceutical composition for atherosclerosis
WO2009099553A3 (en) Use of kinase inhibitor in treatment of atherosclerosis
WO2012145575A3 (en) Therapy for leukemia
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
WO2010098627A2 (ko) 약제학적 제제
EP2275110A3 (en) Cladribine regimen for treating Multiple Sclerosis
JP2007119497A5 (ko)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980114444.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09711817

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009711817

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12918993

Country of ref document: US